SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Northfield Lab(NFLD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (67)7/8/1998 3:07:00 PM
From: Merritt  Read Replies (1) of 148
 
V1: I just talked with Doug Sayles, Assoc. Director of Marketing at Biopure, nice fellow working for what appears to be both an impressive and a smart company. It seems that Biopure has no Phase III trials for Hemopure in the U.S. at present, but...they've completed a Phase II study for use of Hemopure on patients undergoing cardiac surgery, and are trying to get the FDA to consider it a pivotal trial and allow the data to support a PLA for that particular application. If allowed and approved, that would get Hemopure on the market, probably sometime next year. So Cowen wasn't entirely accurate with their reporting, but seemingly accurate with the over-all outlook. It's still a horse race, but with what looks to be a photo finish, instead of a runaway. Thanks for your input, I've learned some things. Still long NFLD though. Merritt
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News